Lymphangiosarcoma is a rare, aggressive malignancy that originates from the endothelial cells lining lymphatic vessels and carries an extremely poor prognosis. Its clinical and histologic features are often indistinguishable from angiosarcoma.
Objective:
We sought to better characterize the clinical and histologic features of lymphangiosarcoma.
Methods:
Case report and review of the literature.
Results:
A number of immunohistochemical markers, including Von Willebrand factor, Ulex europaeus agglutinin 1, CD31, VEGFR-3, D2-40, Prox-1, can be used to help differentiate lymphatic from vascular tissue.
Conclusions:
Recent characterization of several new biologic markers has allowed greater differentiation between these tumors and may provide new therapeutic targets for treatment.
Get full access to this article
View all access options for this article.
References
1.
StewartFWTrevesN. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer1948; 1:64–81.
2.
WoodwardAHIvinsJCSouleEH. Lymphangiosarcoma arising in chronic lymphedematous extremities. Cancer2006;30:562–73, doi:10.1002/1097-0142(197208)30:2<562::AID-CNCR2820300237> 3.0.CO;2-V.
FreedmanAN. Angiosarcoma of the scalp: case report and literature review. Can J Surg1987;30:197–8.
7.
BankaciMMyersENBarnesL. Angiosarcoma of the maxillary sinus: literature review and case report. Head Neck Surg1979;1:274–80, doi:10.1002/hed.2890010311.
8.
CapoVOzzelloLFenoglioCM. Angiosarcomas arising in edematous extremities. Immunostaining for factor VIII-related antigen and ultrastructural features. Hum Pathol1985;16:144–50, doi:10.1016/S0046-8177(85)80063-0.
9.
McWilliamLJHarrisM. Histogenesis of post-mastectomy angiosarcoma - an ultrastructural study. Histopathology1985;9: 331–43, doi:10.1111/j.1365-2559.1985.tb02451.x.
10.
CalonjeEFletcherCDM. Vascular tumors. In: FletcherCDM, editor. Diagnostic histopathology of tumors. 3rd ed.Edinburgh: Churchill Livingstone; 2007. p. 41–76.
11.
WeissSWLasotaJMiettinenMM. Angiosarcoma of soft tissue. In: FletcherCDMUnniKKMertensF, editors. WHO classification tumours of soft tissue and bone. Lyon: IARC Press; 2002. p. 175–7.
12.
OhsawaMNakaNTomitaY. Use of immunohistochemical procedures in diagnosing angiosarcoma. Evaluation of 98 cases. Cancer1995;75:2867–74, doi:10.1002/1097-0142(19950615)75:12 <2867::AID-CNCR2820751212>3.0.CO;2-8.
13.
LalannelNEzzedinelKVergierB. Lymphangiosarcoma revealed by lymphoedema of the neck. Ann Dermatol Venereol2008;89:318–9.
14.
MankeyCCMcHughJBThomasDG. Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas. Histopathology2010;56:364–71, doi:10.1111/j.1365-2559.2010.03484.x.
15.
KahnHJBaileyDMarksA. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Mod Pathol2002;15:434–40, doi:10.1038/modpathol.3880543.
16.
LymboussakiAPartanenTOlofssonB. Expression of the vascular endothelial growth factor C receptor VEGFR-3 in lymphatic endothelium of the skin and in vascular tumors. Am J Pathol1998;153:395–403, doi:10.1016/S0002-9440(10)65583-6.
17.
HoldenCASpittleMFJonesEW. Angiosarcoma of the face and scalp, prognosis and treatment. Cancer1987;59:1046–57, doi:10. 1002/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0. CO;2-6.
18.
MarkRJTranLMSercarzJ. Angiosarcoma of the head and neck: the UCLA experience 1955 through 1990. Arch Otolaryngol Head Neck Surg1993;119:973–8, doi:10.1001/archotol.1993. 01880210061009.
19.
MarkRJPoenJCTranLM. Angiosarcoma: a report of 67 patients and a review of the literature. Cancer1996;77:2400–6, doi:10.1002/(SICI)1097-0142(19960601)77:11<2400::AID-CNCR32 >3.0.CO;2-Z.
20.
VerdierECarvalhoPYoungP. Lymphangiosarcoma treated with liposomal doxorubicin (Caelyx). Ann Dermatol Venereol2007;134:760–3, doi:10.1016/S0151-9638(07)92533-8.
21.
De YaoJTSunDPowellAT. Scalp angiosarcoma remission with bevacizumab and radiotherapy without surgery: a case report and review of the literature. Sarcoma2011;2011:16.369, doi:10. 1155/2011/160369.
22.
LosMRoodhartJMVoestEE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist2007;12:443–50, doi:10. 1634/theoncologist.12-4-443.
23.
KoderaYKantanasakaYKitamuraY. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res2011;13:R66, doi: 10.1186/bcr2903.
24.
MelicharBStudentováHZezulováM. Pazopanib: a new multiple tyrosine kinase inhibitor in the therapy of metastatic renal cell carcinoma and other solid tumors. J BUON2011;16:203–9.
25.
FrattoMEImperatoriMVincenziB. New perspectives: role of sunitinib in breast cancer. Clin Ther2010;161:475–82.
26.
EskensFASteeghsNVerweijJ. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. J Clin Oncol2009;27:4169–76, doi:10.1200/JCO. 2008.18.8193.
